HC Wainwright reiterated their buy rating on shares of TG Therapeutics Inc. (NASDAQ:TGTX) in a report issued on Saturday. They currently have a $18.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $22.00.
Several other research analysts have also recently weighed in on the company. Roth Capital reaffirmed a buy rating and set a $33.00 target price on shares of TG Therapeutics in a research note on Wednesday, August 10th. Brean Capital reiterated a buy rating and issued a $28.00 price target on shares of TG Therapeutics in a research report on Thursday, October 6th. FBR & Co reiterated a buy rating on shares of TG Therapeutics in a research report on Monday, September 19th. S&P Equity Research decreased their price target on TG Therapeutics from $7.15 to $6.40 in a research report on Wednesday, August 24th. Finally, Zacks Investment Research lowered TG Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, July 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $21.21.
TG Therapeutics (NASDAQ:TGTX) traded down 3.80% during mid-day trading on Friday, reaching $6.59. The company’s stock had a trading volume of 1,109,795 shares. TG Therapeutics has a 1-year low of $5.41 and a 1-year high of $14.87. The firm has a 50-day moving average of $7.39 and a 200 day moving average of $7.37. The firm’s market capitalization is $358.87 million.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%. Equities analysts expect that TG Therapeutics will post ($1.22) earnings per share for the current year.
A number of large investors have recently made changes to their positions in the company. BlackRock Advisors LLC increased its stake in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 2,296 shares in the last quarter. Vanguard Group Inc. increased its stake in TG Therapeutics by 11.5% in the second quarter. Vanguard Group Inc. now owns 1,484,133 shares of the biopharmaceutical company’s stock worth $8,995,000 after buying an additional 152,700 shares during the period. SECOR Capital Advisors LP purchased a new stake in TG Therapeutics during the second quarter worth $187,000. Nationwide Fund Advisors increased its stake in TG Therapeutics by 387.7% in the second quarter. Nationwide Fund Advisors now owns 108,904 shares of the biopharmaceutical company’s stock worth $660,000 after buying an additional 86,573 shares during the period. Finally, Oxford Asset Management purchased a new stake in TG Therapeutics during the second quarter worth $475,000. 54.66% of the stock is owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.